Weersink RA, et al. - Researchers sought to develop practical guidance on the safe use of proton pump inhibitors (PPIs) in patients with cirrhosis. Sixty-nine studies on the safety (i.e. adverse events) and pharmacokinetics of PPIs in cirrhotic patients were assessed performing a systematic literature search. As per findings, esomeprazole, omeprazole or rabeprazole use is suggested in patients with Child–Turcotte–Pugh (CTP) A or B cirrhosis and only esomeprazole use is suggested in patients with CTP C. When prescribing PPIs to vulnerable, cirrhotic patients, they suggest considering pharmacokinetic changes as important in addition.